NEW CANAAN, Conn., Aug. 27 /PRNewswire-FirstCall/ --
The first patient to commence on the study at an Ovature site in the EU
has been enrolled at the Catholic University of Leuven, Belgium , under the
direction of
'We are hopeful that a positive outcome of this multi-centre study will be
a significant medical advance for thousands of women with late stage ovarian
cancer whose tumors have become insensitive to the existing chemotherapeutic
drugs,'
'As one of Europe's largest cancer institutions, it is important for us to
be a part of these worldwide studies. It is important that we continue to
develop new ovarian cancer treatments. It is only through constant research
that we will learn how to battle this deadly disease effectively,' said
The Catholic University of Leuven is one of 26 sites in UK and Europe which will be recruiting patients into this major multi-centre multinational ovarian cancer study to determine the safety and effectiveness of the drug phenoxodiol, when used in combination with the chemotherapy drug, carboplatin. Ovarian cancer patients whose cancer initially responded to chemotherapy, but has since become resistant or refractory to traditional platinum treatments are eligible to participate.
There will be an additional 30 sites in the USA, of which 7 are now recruiting patients, and there are 4 sites open in Australia .
The total number of patients to be treated in this pivotal study is 470. The trial consists of two double blind treatment arms. Patients in one trial arm will receive weekly carboplatin and phenoxodiol. Patients in the other trial arm will also receive weekly carboplatin, but a placebo will be substituted for phenoxodiol. Neither patients, nor their doctors will know to which trial arm the patients are randomized.
A change from receiving carboplatin (or cisplatin) in the traditional dose pattern (every two to three weeks) to a weekly carboplatin regimen has been reported to provide a tumor response in some patients with recurrent ovarian cancer (1-3). Thus, in addition to learning more about the safety and efficacy of phenoxodiol, researchers will learn more about the efficacy of weekly carboplatin.
The primary outcome of the trial is the assessment of the relative time it takes for the ovarian cancer to progress. An analysis of interim results will be possible after 95 patients have progressed with their disease.
The trial is being run under arrangements approved by the US Food and Drug Administration (FDA) known as a Special Protocol Assessment (SPA). This provides for the interim analysis of the data, which, if significant, can be used to support a request for grant of marketing approval.
The Chief Executive Officer of
'Over the next 12 to 18 months we expect the interim results from this
multi-national clinical trial which may lead to the first approval for
phenoxodiol,'
In a prior Phase II clinical trial, phenoxodiol was tested in combination with either cisplatin or paclitaxel. Patients with late stage ovarian cancer that had become refractory to platinum or paclitaxel therapy, following multiple courses of chemotherapy, were treated with phenoxodiol and cisplatin or phenoxodiol and paclitaxel, respectively. Of 21 patients in the cisplatin arm there were six partial responders, nine patients with stabilized disease and six patients who had disease progression; of 19 in the paclitaxel arm, there was one complete responder, two partial responders, eleven with stabilized disease and five patients who had disease progression. There were few side effects associated with phenoxodiol, but, as with any investigational drug, there is a possibility of unexpected side effects.
Women who are interested in participating in the OVATURE trial, or who simply wish to learn more about this study, should visit http://www.OVATUREtrial.com or visit http://clinicaltrials.gov/ (type OVATURE in the search box).
About phenoxodiol: Phenoxodiol is being developed as a therapy for late- stage, chemo-resistant prostate, ovarian and cervical cancers. Phenoxodiol is an investigational drug and, as such, is not commercially available. It is a novel-acting drug that inhibits key pro-survival signaling pathways operating via sphingosine-1-phosphate and Akt. Inhibition of these pathways leads to prevention of phosphorylation of key anti-apoptotic proteins such as XIAP. Loss of activity of these proteins restores the ability of chemoresistant tumor cells to undergo apoptosis in response to chemotherapy. The putative molecular target for phenoxodiol is a tumor-specific protein, accounting for the highly selective nature of the drug.
About
1. Piura B and Meirovitz M. Weekly single-agent carboplatin in heavily
pretreated patients with recurrent ovarian, peritoneal and fallopian
tube carcinoma. Eur J Gynaecol Oncol. 2005;26(4):386-90.
2. van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC,
de Wit R, Stoter G, Verweij J. What is the role of dose-dense
therapy? Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:233-240.
3. CaDron I, Leunen K, Amant F, Van Grop T, Neven P, Vergote I. The
'Leuven' dose dense paclitaxel/carboplatin regimen in patients with
recurrent ovarian cancer. Gynecol Oncol 2007, in press.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third arty patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
SOURCE
